Biocartis From inspiration to IPO and beyond Hilde Windels | Bolero event | 17 October 2015

2

NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. Unless required by applicable law or regulation, no person is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents. This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results of operations, financial condition, liquidity, performance, prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, liquidity and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation. This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. The Company's shares have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration requirement thereof.

Biocartis brings innovative solutions enabling accurate, fast and effective diagnosis, treatment selection and treatment monitoring.

Biocartis mission statement

3

IdyllaTM best-in-class

• Fully automated sample-to-result

• Accurate results

• Any sample type

• Short turnaround time

• Easy to use

• Multiplexing

• Scalable

• Connectivity

4

From Inspiration to IPO

5

6

idea

prototype

industrialisation

manufacturing

sales

IPO

Early history First steps – Proof of concept and initial fundraising

• Proof of concept for multiplexed detection of DNA and RNA based biomarkers

2007 2008 2009 2010

• July 2007: • Initial investment

EUR 67,000

• July 2008: • Raised EUR 1.25

million

• October 2009: • EUR 10 million

Series A financing

• Biocartis founded in Lausanne Switzerland

• Acquired rights for multiplex detection platform from University of Ghent and Tibotec-Virco (J&J)

• First proof of concept for multiplexed immunoassays

• April 2010: • EUR 44 million

Series B financing

• Acquired tech platform for automated DNA / RNA testing (“Apollo”)

8

Towards commercialisation Gaining momentum in a competitive market

• Platform renamed Idylla™

• Ended collaboration with bioMérieux

2011 2012 2013 2014

• November 2011: • EUR 58.6 million

Series C financing

• December 2012: • EUR 34.5 million

Series D Financing

• December 2013: • EUR 30 million

Series E financing

• Relocated research and development to Mechelen, Belgium

• Established pilot manufacturing line

• Collaborations with Philips, Genome Research and Wellcome Trust

• April 2014: • EUR 65 million

Series F financing

• Strategic collaboration with Abbott Molecular

• 2010 J&J agreement restructured to suit both parties

10

12

13

GROW

Innovators

Early Adopters

Early Majority EXPAND

SEED

Continued expansion global commercial footprint

• > 50 countries covered through direct and indirect sales channels

• Direct sales force covering 16 European countries

• Nine new distribution contracts signed in H1 2015: – 12 additional countries – Minimum purchase obligations > 100

IdyllaTM instruments over coming 3 years

Direct – reps on the ground

Partnership under discussion

2015/16

2016/17

2017

2016

Status as of 30 June 2015

Distributors – signed up

Distributors – under discussion

14

15

IPO… the start of a marathon

16

• IPO was in a 6.5x oversubscribed • IPO attracted a wide interest from a mix of long-

term, specialist investors across continental Europe, the UK and the US

• April 2015: • EUR 115 million IPO

Next steps

18

Open platform Launch of 4-5 assays a year

19

IdyllaTM menu strategy

Strategic partnerships Diagnostic app developer

partnerships

20

Oncology

Infectious Diseases

Our diagnostic app store Intention to launch at least 4 to 5 assays per year

ON

COLO

GY

INFE

CTIO

US

DIS

EASE

S

2014 2015 2016 2017 KRAS (colon) NRAS (colon)

MSI

ctKRAS***

ctNRAS***

LC** (lung)

BRAF (melanoma) undisclosed assay

undisclosed assay

undisclosed assay

NRAS / BRAF (colon) NRAS / BRAF / EGFR492 (colon)***

Ebola*

Respiratory mixed panel

Sepsis Influenza Virus –

Respiratory Syncytial Virus+

Influenza Virus – Surveillance+

HIV-VL++

HBV-VL

HCV-VL

ctLC***

* Emergency Use Authorization label ** LC is the code name for an undisclosed Lung Cancer test *** research use only

+ J&J test ++ Biocartis test in collaboration with J&J

ctBRAF***

We often have to remind people...

22

The people behind the story are at least as important as the technology.

25

Our Biocartis DNA

• Surface tensions, think solutions

• Work hard, have fun

• Put your heart in what you do

• Take up responsibility

• Respect is an attitude

• Dare to fail

Sense - Think - Share - Do

27

Making personalised medicine sustainable for society

29

Contact

Biocartis Investor Relations Generaal De Wittelaan 11 B3 2800 Mechelen Belgium tel. +32 15 63 17 29 ir@biocartis.com www.investors.biocartis.com